Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked ...
Please provide your email address to receive an email when new articles are posted on . Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory ...
Dr. Pravin Dugel said the company’s key development was the SOL-1 Phase III wet AMD result for AXPAXLI, stating: "SOL-1 has fundamentally changed the conversation in wet AMD." He added: "In February, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results